TRIPTORELIN
Information current as at: 1 September 2026
Submission Details
- Brand name:
-
- Diphereline®
- Form and strength:
-
- Intramuscular (I.M.) injection 3.75 mg with solvent, syringe and needles
- Submission sponsor:
- IPSEN PTY LTD
- Condition/indication:
(therapeutic use) -
- Treatment with gonadotrophin releasing hormone (GnRH) agonist
- Listing requested:
- To request a change to the PBS listing for triptorelin 3.75 mg I.M. injection to support its use across a number of women’s health conditions.
- Funding program:
- General schedule
- Request authority level:
- Unrestricted Benefit
- PBAC Submission type:
- Change to existing listing (Category 2)
- Comment:
- Special Out of Session July 2026 PBAC Meeting
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - November 2026 PBAC meeting
-
Opportunity for consumer comment: - --
-
PBAC meeting: - Held on 04/11/2026
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Exception applied
-
Lodgement of required documentation: - 17/08/2026
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 20/08/2026
-
Status:
- Finalised
-
7Government processes:
- Commenced on 21/08/2026
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
The PBAC recommended that the General Benefit listing for triptorelin 3.75 mg intramuscular
(IM)
injection be made unrestricted. The PBAC’s recommendation for listing was based on,
among
other matters, its assessment that the cost effectiveness of triptorelin 3.75 mg for
a broader
population would be acceptable if it were cost minimised against goserelin 3.6 mg
subcutaneous
implant (SCI). The PBAC considered that goserelin 3.6 mg SCI was an appropriate comparator.
The
PBAC advised that an unrestricted listing would align with contemporary and evidence-based
clinical practice. The PBAC advised that a review of triptorelin 3.75 mg utilisation
should be
completed around 2 years after the amendment to the PBS listing to determine whether
there are
any changes to the expected utilisation.